Nettet1. okt. 2024 · Monika Kijanska, Ph.D, is on a mission to develop and provide 3D culture solutions for testing the safety and efficacy of drugs. She is a senior scientist and team lead of Liver Solutions at InSphero, a biotech company specializing in 3D cell culture technology for drug safety and efficacy testing.. Traditionally, drug safety testing was … NettetIn honor of the inaugural International NASH Day, Insphero explains why we need better preclinical models for non-alcoholic steatohepatitis (NASH) disease drug discovery.. …
3D InSight™ Human Liver Microtissues, Human Liver …
NettetLiver Disease; Oncology. Efficacy Testing; Immuno-Oncology; PRODUCTS. 3D InSight™ Platforms; Liver. Liver Disease. Steatosis; ... InSphero's Akura™ technology platforms … Nettet29. sep. 2015 · InSphero Dr. Randy Strube Director of Global Marketing +1 800-779-7558 ext. 102 [email protected] or Dr. Jan Lichtenberg CEO and Co-Founder … one cultural heritage of ilocos norte
Liver-on-a-Chip Models of Fatty Liver Disease. - Abstract - Europe …
Nettet19. okt. 2024 · Here, a scalable, gravity-driven microfluidic system featuring 3D microtissues (MTs) that represent different organs for the prediction of drug–drug interactions is used. Human liver microtissues (hLiMTs) are combined with tumor microtissues (TuMTs) and treated with drug combinations that are known to cause … Nettet16. mar. 2024 · 30.05.2016 InSphero Launches Multi-donor Human Liver Microtissues for Prediction of Drug-induced Liver Injury; 08.07.2015 TOP 100 Startup Award winner InSphero secures CHF 20 million series C financing; ... 27.02.2014 InSphero granted hanging drop patents in China and Japan; NettetInSphero assay-ready organoids are engineered and certified for use in critical drug development applications and validated to ensure uniform size, robust functionality, and … one culver building